Does the media favor HIMS or DFTX?

In the previous week, Definium Therapeutics had 1 more articles in the media than Hims & Hers Health. MarketBeat recorded 11 mentions for Definium Therapeutics and 10 mentions for Hims & Hers Health. Definium Therapeutics' average media sentiment score of 0.89 beat Hims & Hers Health's score of 0.69 indicating that Definium Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Definium Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DFTX or PACS?

In the previous week, Definium Therapeutics had 2 more articles in the media than PACS Group. MarketBeat recorded 11 mentions for Definium Therapeutics and 9 mentions for PACS Group. Definium Therapeutics' average media sentiment score of 0.89 beat PACS Group's score of 0.51 indicating that Definium Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PACS Group 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DFTX or BLLN more profitable?

Billiontoone's return on equity of 0.00% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Definium Therapeutics N/A -100.30% -69.22% Billiontoone N/A N/A N/A

Does the media favor DFTX or BLLN?

In the previous week, Billiontoone had 4 more articles in the media than Definium Therapeutics. MarketBeat recorded 15 mentions for Billiontoone and 11 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.89 beat Billiontoone's score of 0.32 indicating that Definium Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Billiontoone 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Definium Therapeutics (DFTX) Competitors

$46.15 +0.17 (+0.37%)

As of 02:09 PM Eastern

Compare

DFTX vs. BTSG, FMS, HIMS, PACS, and BLLN

Should you buy Definium Therapeutics stock or one of its competitors? MarketBeat compares Definium Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Definium Therapeutics include BrightSpring Health Services (BTSG), Fresenius Medical Care AG & Co. KGaA (FMS), Hims & Hers Health (HIMS), PACS Group (PACS), and Billiontoone (BLLN). These companies are all part of the "healthcare" industry.

How does Definium Therapeutics compare to BrightSpring Health Services?

BrightSpring Health Services (NASDAQ:BTSG) and Definium Therapeutics (NASDAQ:DFTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

In the previous week, BrightSpring Health Services had 5 more articles in the media than Definium Therapeutics. MarketBeat recorded 16 mentions for BrightSpring Health Services and 11 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.89 beat BrightSpring Health Services' score of 0.44 indicating that Definium Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BrightSpring Health Services	4 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Definium Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BrightSpring Health Services has a net margin of 2.27% compared to Definium Therapeutics' net margin of 0.00%. BrightSpring Health Services' return on equity of 14.63% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BrightSpring Health Services	2.27%	14.63%	4.41%
Definium Therapeutics	N/A	-100.30%	-69.22%

BrightSpring Health Services has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than BrightSpring Health Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BrightSpring Health Services	$12.91B	1.05	$190.67M	$1.41	48.91
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A

BrightSpring Health Services currently has a consensus target price of $70.12, indicating a potential upside of 1.66%. Definium Therapeutics has a consensus target price of $49.23, indicating a potential upside of 6.68%. Given Definium Therapeutics' higher probable upside, analysts plainly believe Definium Therapeutics is more favorable than BrightSpring Health Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BrightSpring Health Services	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	3.00
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

BrightSpring Health Services has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.2, suggesting that its stock price is 120% more volatile than the broader market.

27.9% of Definium Therapeutics shares are owned by institutional investors. 2.8% of BrightSpring Health Services shares are owned by company insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

BrightSpring Health Services beats Definium Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Definium Therapeutics compare to Fresenius Medical Care AG & Co. KGaA?

Definium Therapeutics (NASDAQ:DFTX) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Definium Therapeutics had 7 more articles in the media than Fresenius Medical Care AG & Co. KGaA. MarketBeat recorded 11 mentions for Definium Therapeutics and 4 mentions for Fresenius Medical Care AG & Co. KGaA. Fresenius Medical Care AG & Co. KGaA's average media sentiment score of 1.30 beat Definium Therapeutics' score of 0.89 indicating that Fresenius Medical Care AG & Co. KGaA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fresenius Medical Care AG & Co. KGaA	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Definium Therapeutics presently has a consensus target price of $49.23, indicating a potential upside of 6.68%. Fresenius Medical Care AG & Co. KGaA has a consensus target price of $28.00, indicating a potential upside of 16.12%. Given Fresenius Medical Care AG & Co. KGaA's higher probable upside, analysts plainly believe Fresenius Medical Care AG & Co. KGaA is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Fresenius Medical Care AG & Co. KGaA	4 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.56

Fresenius Medical Care AG & Co. KGaA has a net margin of 4.88% compared to Definium Therapeutics' net margin of 0.00%. Fresenius Medical Care AG & Co. KGaA's return on equity of 8.90% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-100.30%	-69.22%
Fresenius Medical Care AG & Co. KGaA	4.88%	8.90%	4.05%

Definium Therapeutics has a beta of 2.2, indicating that its share price is 120% more volatile than the broader market. Comparatively, Fresenius Medical Care AG & Co. KGaA has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 8.4% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A
Fresenius Medical Care AG & Co. KGaA	$19.36B	0.67	$1.11B	$1.90	12.69

Summary

Fresenius Medical Care AG & Co. KGaA beats Definium Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Definium Therapeutics compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Hims & Hers Health presently has a consensus target price of $30.70, suggesting a potential downside of 17.63%. Definium Therapeutics has a consensus target price of $49.23, suggesting a potential upside of 6.68%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Definium Therapeutics is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Definium Therapeutics has a net margin of 0.00% compared to Hims & Hers Health's net margin of -0.56%. Hims & Hers Health's return on equity of 6.10% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-0.56%	6.10%	1.52%
Definium Therapeutics	N/A	-100.30%	-69.22%

Hims & Hers Health has higher revenue and earnings than Definium Therapeutics. Hims & Hers Health is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	3.67	$128.37M	-$0.09	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A

In the previous week, Definium Therapeutics had 1 more articles in the media than Hims & Hers Health. MarketBeat recorded 11 mentions for Definium Therapeutics and 10 mentions for Hims & Hers Health. Definium Therapeutics' average media sentiment score of 0.89 beat Hims & Hers Health's score of 0.69 indicating that Definium Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Definium Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hims & Hers Health has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.2, suggesting that its stock price is 120% more volatile than the broader market.

63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are held by institutional investors. 11.8% of Hims & Hers Health shares are held by company insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Hims & Hers Health and Definium Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Definium Therapeutics compare to PACS Group?

Definium Therapeutics (NASDAQ:DFTX) and PACS Group (NYSE:PACS) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

27.9% of Definium Therapeutics shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by company insiders. Comparatively, 70.1% of PACS Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Definium Therapeutics had 2 more articles in the media than PACS Group. MarketBeat recorded 11 mentions for Definium Therapeutics and 9 mentions for PACS Group. Definium Therapeutics' average media sentiment score of 0.89 beat PACS Group's score of 0.51 indicating that Definium Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PACS Group	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Definium Therapeutics currently has a consensus price target of $49.23, suggesting a potential upside of 6.68%. PACS Group has a consensus price target of $50.60, suggesting a potential upside of 11.15%. Given PACS Group's higher possible upside, analysts clearly believe PACS Group is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

PACS Group has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A
PACS Group	$5.29B	1.36	$191.54M	$1.56	29.18

Definium Therapeutics has a beta of 2.2, meaning that its share price is 120% more volatile than the broader market. Comparatively, PACS Group has a beta of -0.08, meaning that its share price is 108% less volatile than the broader market.

PACS Group has a net margin of 4.49% compared to Definium Therapeutics' net margin of 0.00%. PACS Group's return on equity of 26.47% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-100.30%	-69.22%
PACS Group	4.49%	26.47%	4.36%

Summary

PACS Group beats Definium Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Definium Therapeutics compare to Billiontoone?

Definium Therapeutics (NASDAQ:DFTX) and Billiontoone (NASDAQ:BLLN) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

In the previous week, Billiontoone had 4 more articles in the media than Definium Therapeutics. MarketBeat recorded 15 mentions for Billiontoone and 11 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.89 beat Billiontoone's score of 0.32 indicating that Definium Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Billiontoone	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Definium Therapeutics currently has a consensus target price of $49.23, suggesting a potential upside of 6.68%. Billiontoone has a consensus target price of $126.00, suggesting a potential downside of 1.49%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Definium Therapeutics is more favorable than Billiontoone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Billiontoone has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A
Billiontoone	$354.54M	16.59	$7.45M	$0.55	232.56

27.9% of Definium Therapeutics shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Billiontoone's return on equity of 0.00% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-100.30%	-69.22%
Billiontoone	N/A	N/A	N/A

Summary

Definium Therapeutics and Billiontoone tied by winning 7 of the 14 factors compared between the two stocks.

Get Definium Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DFTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DFTX vs. The Competition

Export

Metric	Definium Therapeutics	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.60B	$525.72M	$6.78B	$12.65B
Dividend Yield	N/A	3.90%	2.68%	8.43%
P/E Ratio	-18.53	3.14	27.13	24.40
Price / Sales	N/A	6,334.68	525.28	91.46
Price / Cash	N/A	13.13	48.59	59.39
Price / Book	13.74	87.66	10.85	6.33
Net Income	-$183.79M	-$96.07M	$3.59B	$331.45M
7 Day Performance	1.83%	-0.09%	-1.34%	0.18%
1 Month Performance	94.15%	2.34%	2.96%	-0.72%
1 Year Performance	471.87%	62.18%	28.93%	20.53%

Definium Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DFTX Definium Therapeutics	2.3057 of 5 stars	$46.15 +0.4%	$49.23 +6.7%	+452.0%	$4.60B	N/A	N/A	40	Gap Down
BTSG BrightSpring Health Services	3.3189 of 5 stars	$69.64 -2.5%	$68.41 -1.8%	+243.0%	$14.09B	$12.91B	49.39	23,500	News Coverage Analyst Forecast
FMS Fresenius Medical Care AG & Co. KGaA	4.3168 of 5 stars	$24.46 +1.8%	$28.00 +14.5%	-11.1%	$12.90B	$22.20B	12.87	1,488	Positive News
HIMS Hims & Hers Health	3.0425 of 5 stars	$34.40 +0.0%	$30.70 -10.7%	-32.4%	$7.96B	$2.35B	N/A	2,442	Analyst Upgrade
PACS PACS Group	3.1589 of 5 stars	$43.29 +0.2%	$50.60 +16.9%	+246.7%	$6.84B	$5.29B	27.75	47,455

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DFTX) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Definium Therapeutics (DFTX) Competitors

DFTX vs. BTSG, FMS, HIMS, PACS, and BLLN

How does Definium Therapeutics compare to BrightSpring Health Services?

Summary

How does Definium Therapeutics compare to Fresenius Medical Care AG & Co. KGaA?

Summary

How does Definium Therapeutics compare to Hims & Hers Health?

Summary

How does Definium Therapeutics compare to PACS Group?

Summary

How does Definium Therapeutics compare to Billiontoone?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFTX vs. The Competition

Definium Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Definium Therapeutics (DFTX) Competitors

DFTX vs. BTSG, FMS, HIMS, PACS, and BLLN

How does Definium Therapeutics compare to BrightSpring Health Services?

Does the media prefer BTSG or DFTX?

Is BTSG or DFTX more profitable?

Which has higher earnings and valuation, BTSG or DFTX?

Do analysts recommend BTSG or DFTX?

Which has more risk and volatility, BTSG or DFTX?

Do insiders & institutionals believe in BTSG or DFTX?

Summary

How does Definium Therapeutics compare to Fresenius Medical Care AG & Co. KGaA?

Does the media favor DFTX or FMS?

Do analysts rate DFTX or FMS?

Is DFTX or FMS more profitable?

Which has more risk and volatility, DFTX or FMS?

Do institutionals & insiders believe in DFTX or FMS?

Which has better valuation and earnings, DFTX or FMS?

Summary

How does Definium Therapeutics compare to Hims & Hers Health?

Do analysts recommend HIMS or DFTX?

Is HIMS or DFTX more profitable?

Which has higher earnings & valuation, HIMS or DFTX?

Does the media favor HIMS or DFTX?

Which has more volatility and risk, HIMS or DFTX?

Do institutionals and insiders hold more shares of HIMS or DFTX?

Summary

How does Definium Therapeutics compare to PACS Group?

Do institutionals and insiders hold more shares of DFTX or PACS?

Does the media refer more to DFTX or PACS?

Do analysts prefer DFTX or PACS?

Which has stronger earnings and valuation, DFTX or PACS?

Which has more risk and volatility, DFTX or PACS?

Is DFTX or PACS more profitable?

Summary

How does Definium Therapeutics compare to Billiontoone?

Does the media favor DFTX or BLLN?

Do analysts prefer DFTX or BLLN?

Which has preferable earnings and valuation, DFTX or BLLN?

Do institutionals & insiders have more ownership in DFTX or BLLN?

Is DFTX or BLLN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFTX vs. The Competition

Definium Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools